Skip to content
Sample Page
Author:
Silexion Therapeutics Corp
Posted Date:
June 23, 2026
Silexion Therapeutics Receives Approval from Germany’s BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp
June 23, 2026
Silexion Therapeutics to Attend BIO International Convention 2026
Silexion Therapeutics Corp
June 16, 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Silexion Therapeutics Corp
May 26, 2026
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics Corp
May 18, 2026
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
Silexion Therapeutics Corp
May 15, 2026
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
Silexion Therapeutics Corp
May 14, 2026
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics Corp
May 13, 2026
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp
April 28, 2026
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp
March 24, 2026
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Silexion Therapeutics Corp
March 24, 2026
1
2
Next
